ArticleEuropean journal of haematology2025

Efficacy and Safety of Bendamustine-Rituximab for Nodular Lymphocyte Predominant Hodgkin Lymphoma.

Alexander Robin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.